Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow.

Journal of molecular medicine (Berlin, Germany) - 1 Jan 2014

Xu Jingjing, Zhou Peng, Wang Wenjuan, Sun Aining, Guo Feng

Abstract excerpt

UNLABELLED: Although the biological factors that contribute to the pathogenesis of chronic lymphocytic leukemia (CLL) remain widely unresolved, it has been suggested that dysregulated cell survival and proliferation are fundamental to this process. Constitutive classical nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation protects CLL B-cells from cell death and plays a critical role...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemokines
Share to Coculture Techniques

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunoglobulin Heavy Chains

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Mesenchymal Stem Cells

Share to Proteasome Inhibitors

Share to Receptor, Notch1

Share to Transcription Factor RelA

Source

Identifiers

PMID: 24042463
DOI: 10.1007/s00109-013-1081-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow.PMID 24042463Read ↗

NF-kB and the CLL microenvironmentSemantic proximity Read ↗

The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphomaSemantic proximity Read ↗

NF-κB as a therapeutic target in chronic lymphocytic leukemiaSemantic proximity Read ↗

Rel A Is an Independent Biomarker of Clinical Outcome in Chronic Lymphocytic LeukemiaSemantic proximity Read ↗

The NF-κB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic targetSemantic proximity Read ↗

NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions.Semantic proximity Read ↗

Molecular Interactions Between Innate and Adaptive Immune Cells in Chronic Lymphocytic Leukemia and Their Therapeutic ImplicationsSemantic proximity Read ↗

NF-κB in Hematological MalignanciesSemantic proximity Read ↗

Frequent Engagement of RelB Activation Is Critical for Cell Survival in Multiple MyelomaSemantic proximity Read ↗

RelB Upregulates PD-L1 and Exacerbates Prostate Cancer Immune EvasionSemantic proximity Read ↗

c-Rel Is the Pivotal NF-κB Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA StudySemantic proximity Read ↗

Constitutive NF-κB activation in AML: Causes and treatment strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.